TheraRadar
Data updated: May 26, 2026

DICHLORPHENAMIDE

Carbonic Anhydrase Inhibitors
Rare Disease Approved 2025-11-18

Dichlorphenamide is an oral medication used for patients who experience primary hyperkalemic or hypokalemic periodic paralysis. It also helps those with related variants of these conditions. This medication is prescribed to help manage the episodes of paralysis associated with these specific disorders.

Source: FDA Label • RISING • Carbonic Anhydrase Inhibitor
Jump to: Indications Approvals Trials Competitors Similar Safety Patents

How DICHLORPHENAMIDE Works

This drug works by inhibiting the enzyme carbonic anhydrase. While it is known to target this specific enzyme, the exact process by which this action helps patients with periodic paralysis is not yet fully understood.

Source: FDA Label
1
Indication
--
Phase 3 Trials
0
Years on Market

Details

Status
Prescription
First Approved
2025-11-18
Routes
ORAL
Dosage Forms
TABLET

Companies

RISING
Active Ingredient: DICHLORPHENAMIDE

DICHLORPHENAMIDE Approval History

2026
Original
New Indication
New Form
Label Update
1 FDA actions from 2025 to 2025
Nov 2025 ORIGINAL
Update

What DICHLORPHENAMIDE Treats

2 indications

DICHLORPHENAMIDE is approved for 2 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Hyperkalemic Periodic Paralysis
  • Hypokalemic Periodic Paralysis
Source: FDA Label

DICHLORPHENAMIDE Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

MoA expansion candidates

7

Same target(s), different indications — where else is this mechanism being explored?

ZONISADE
AZURITY
2022 1 indic.
EPRONTIA
AZURITY
2021 5 indic.
Unlock 5 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to DICHLORPHENAMIDE

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

KEVEYIS
DICHLORPHENAMIDE
2 shared
XERIS
Shared indications:
Hyperkalemic Periodic ParalysisHypokalemic Periodic Paralysis
ORMALVI
DICHLORPHENAMIDE
2 shared
TORRENT
Shared indications:
Hyperkalemic Periodic ParalysisHypokalemic Periodic Paralysis
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

ClinicalTrials.gov ↗ Pro

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

DICHLORPHENAMIDE FDA Label Details

Indications & Usage

DICHLORPHENAMIDE is indicated for the treatment of Hyperkalemic Periodic Paralysis; Hypokalemic Periodic Paralysis.

Looking for the branded version?

KEVEYIS

Full clinical data, patents, trials, and competitive landscape for dichlorphenamide.

See KEVEYIS

Data Sources

FDA Approval: ANDA218783 → Label: DailyMed → Trials: ClinicalTrials.gov →

Data sourced from official FDA and NIH databases. Click links to verify on original sources.